Pharmocann teams with Shamir Institute on magic mushrooms
A joint company will examine using psilocybin mushroom-based drugs to treat Alzheimer’s and depression.
Archives: news
Diamond Therapeutics Announces First Patient Dosed in Health Canada Approved Trial Evaluating Low-Dose Psilocybin
World’s first systematic, pharmacokinetic/pharmacodynamic study of non-psychedelic doses of psilocybin.
Expert: MDMA Is Very Likely to Be FDA-Approved for PTSD by the End of 2023
Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses common themes or key points being raised in the field of psychedelic medicine at recent conferences.
The club is bumping: Recreational ketamine use on the rise, Langone study finds
According to a study conducted at NYU Langone, nonmedical ketamine availability has risen in recent years, but usage still remains limited to below 1% of the general population.
Creso Pharma’s subsidiary Halucenex’s key psychedelic ingredient passes crucial testing and is one step closer to phase two clinical trials
In a major step towards a Phase II clinical trial Halucenex has received favourable results from stability testing for its GMP grade psilocybin.
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
PharmaTher announces it has entered into an agreement with Alcami Corporation for the clinical and commercial manufacturing of the company’s proprietary ketamine products.
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies
Cybin today announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies.
First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial
Small Pharma today announced that the first patient has been dosed in the company’s Phase IIa clinical trial for its lead DMT candidate, SPL026, which, in combination with psychotherapy, is intended to serve as a possible treatment of Major Depressive Disorder.
Emyria passes MDMA analogue development milestone with Eurofins to lead extensive compound screening program
Emyria has selected Eurofins – a world leader in pharmaceutical product testing – to lead an extensive compound screening program for its exclusive MDMA-analogue library.
This Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic
Pasithea Therapeutics announced that its wholly-owned subsidiary Pasithea Clinics has partnered with ZEN Healthcare to offer intravenous (IV) ketamine therapy to patients suffering from treatment-resistant mental health issues.